Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

Fig. 1

Mean changes from baseline to week 12/ET for WPAI domains. Except for “daily activity impairment,” only full-time paid workers and part-time paid workers were included (not homemakers). Higher WPAI scores indicate greater activity impairment and less productivity. WPAI outcomes are expressed as impairment percentages. All time points except for week 12/ET are observed data. At week 12/ET, last observation carried forward was used for missing WPAI scores. p values calculated using analysis of covariance, with no adjustment made for multiplicity. *p<0.05; **p<0.01; ***p<0.001, peficitinib versus placebo. ET early termination, WPAI Work Productivity and Activity Impairment

Back to article page